CTA Investigational Product Management 1 — Questions and Answers
Question 1: What is the primary purpose of an Investigational Product (IP) accountability log in clinical trials?
- To record the financial cost of each drug shipment
- To track receipt, dispensing, return, and destruction of all IP at the site (Correct answer)
- To document participant adverse reactions to the study drug
- To schedule upcoming drug shipments from the sponsor
Correct answer: To track receipt, dispensing, return, and destruction of all IP at the site
The IP accountability log provides a complete chain-of-custody record for all investigational product at the site, ensuring every unit is accounted for from receipt through destruction.
Question 2: According to GCP guidelines, where should investigational products be stored at a clinical trial site?
- In any secure location chosen by the principal investigator
- In a designated, secure area under conditions specified by the sponsor protocol (Correct answer)
- In the same refrigerator used for routine laboratory samples
- In the CTA's office for easy access during participant visits
Correct answer: In a designated, secure area under conditions specified by the sponsor protocol
GCP requires IP to be stored in a secure, designated area that meets the temperature, humidity, and light conditions specified by the sponsor to maintain product integrity.
Question 3: What document typically authorizes the shipment of investigational products to a clinical trial site?
- The site's IRB approval letter
- The executed Clinical Trial Agreement (CTA) contract
- The site initiation visit report
- The drug shipment authorization or IP release letter from the sponsor (Correct answer)
Correct answer: The drug shipment authorization or IP release letter from the sponsor
The sponsor issues an IP release or shipment authorization confirming the site is approved and all necessary regulatory documents are in place before shipping investigational product.
Question 4: Who is typically responsible for dispensing investigational products to study participants at a clinical site?
- The Clinical Trial Associate (CTA) assigned to the study
- The sponsor's medical monitor
- A qualified pharmacist or authorized designee as specified in the protocol (Correct answer)
- The IRB coordinator
Correct answer: A qualified pharmacist or authorized designee as specified in the protocol
IP dispensing must be performed by a licensed pharmacist or another authorized individual explicitly designated in the protocol or site pharmacy procedures to ensure accurate dosing and documentation.
Question 5: What is the correct procedure when unused investigational product is returned by a study participant?
- Dispense the returned product to the next enrolled participant immediately
- Document the return in the IP accountability log and quarantine per protocol instructions (Correct answer)
- Discard the product in regular trash to maintain confidentiality
- Ship the returned product back to the sponsor within 24 hours
Correct answer: Document the return in the IP accountability log and quarantine per protocol instructions
Returned IP must be logged in the accountability record and quarantined according to protocol; it cannot be re-dispensed unless explicitly permitted, and destruction follows sponsor instructions.
Question 6: Which regulatory requirement primarily governs the labeling of investigational medicinal products in the United States?
- 21 CFR Part 312 (IND regulations) (Correct answer)
- ICH E6 Good Clinical Practice guideline
- ISO 14155 standard for medical device trials
- FDA's Guidance for Industry on Electronic Records
Correct answer: 21 CFR Part 312 (IND regulations)
21 CFR Part 312 outlines the IND requirements including mandatory labeling elements for investigational drugs, such as the statement 'Caution: New Drug – Limited by Federal law to investigational use.'
Question 7: What does 'blinding' refer to in the context of investigational product management?
- Removing the lot number from IP packaging to conceal manufacturing data
- The process of withholding treatment assignment from participants and/or site staff to minimize bias (Correct answer)
- Encrypting IP shipment manifests to protect proprietary formulas
- Covering drug labels during participant visits to prevent accidental disclosure
Correct answer: The process of withholding treatment assignment from participants and/or site staff to minimize bias
Blinding conceals treatment assignment (active drug vs. placebo) from participants and/or investigators to prevent bias in outcome assessment and participant behavior.
CTA Investigational Product Management 1
What is the primary purpose of an Investigational Product (IP) accountability log in clinical trials?